Our Leadership Team
Kevin Bassett, MBA
President & CEO
Kevin is a certified public accountant (inactive license). He holds an M.B.A. from the Carlson School of Management at the University of Minnesota and a B.A. in Accounting and English from St. John’s University. Kevin also served as an officer in the United States Army Reserves from 1991-2001.
Mark Ereth, MD
Chief Medical Officer
Chief Science Officer
Bill holds a B.S. from the University of Minnesota with a double major in Chemical Engineering and Biology.
Kay Warnott, MSN
Clinical Areas of Expertise: Acute pain management, cardiovascular, cardiothoracic and pulmonary diseases, and thrombotic syndromes in both adults and pediatrics.
Kevin Barrett, MBA
Chief Operating Officer
Kevin holds an M.B.A. from the Carlson School of Management at the University of Minnesota and a B.A. in Business from the University of St. Thomas.
Rita Pendergrass joined InSitu Biologics in December 2019 as Director of Clinical Operations. Rita has over 30 years of experience in the biotech industry in both pharmaceutical drug products and medical devices. She has overseen Phase I-IV clinical trials, including facets such as budget preparation, contract negotiation, and all clinical study activities from site setup through the final clinical study report. Rita has also collaborated in the completion of successful regulatory submissions from IND to NDA approval for multiple drug products.
Rita has a degree in Business Administration and is a certified research associate in clinical trials.
Board of Directors
James Knapp, CFP
President & CEO
Kevin Bassett joined InSitu Biologics in September 2019 as President and CEO. Prior to joining InSitu, Kevin was General Manager of HLT Medical, a clinical-stage company developing a next-generation heart valve in the field of Transcatheter Aortic Valve Replacement (TAVR). Kevin has also served in a variety of senior executive roles in early-stage medical technology companies over the past 20 years.
Andy Lafrence, CPA
Dr. Robert Wilson, MD